longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

Tip Ranks
Aug 13, 2026 at 12:45 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Canaccord Genuity analyst Gary Nachman reiterated a Buy rating on Scholar Rock Holding (SRRK) with a $62 price target, while shares closed at $53.82. The broader analyst consensus remains a Strong Buy with an average target of $62.10, implying 15.38% upside. Additionally, J.P. Morgan maintained its Buy rating with a $63 target.

Canaccord Genuity analyst Gary Nachman reiterated a Buy rating on Scholar Rock Holding yesterday and set a price target of $62.00. The company’s shares closed yesterday at $53.82.

Claim 55% Off TipRanks

  • Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
  • Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Nachman is a 2-star analyst with an average return of 0.5% and a 46.31% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Achieve Life Sciences.

Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $62.10, implying a 15.38% upside from current levels. In a report released today, J.P. Morgan also maintained a Buy rating on the stock with a $63.00 price target.

Login to unlock443characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Scholar Rock

Scholar Rock

USSRRK

-0.47%

Ionis Pharma

Ionis Pharma

USIONS

Jazz Pharma

Jazz Pharma

USJAZZ

LongbridgeAI